Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)
A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 342 participants.
Also called NCT05714085
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2/3
- Enrolled
- 342 participants
- Sponsor
- Registry
-
NCT05714085 -
2022-501238-52-00 -
U1111-1275-1768 -
2021-004399-33
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Belgium, Brazil, Canada, Colombia, Croatia, Denmark, Finland, France, Germany, Hungary, Ireland, Italy, Malaysia, Mexico, Netherlands, New Zealand, Peru, Poland, Portugal, Saudi Arabia, Serbia, Singapore, South Africa, South Korea, Spain, Sweden, Thailand, Türkiye, United Kingdom
- Registry status
- Recruiting
Technical summary
Registry record NCT05714085. Randomized; quadruple masking; primary purpose treatment. Start 2023-05-31 (actual); primary completion 2029-08-20 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)
- Condition
- Heart Failure
- Condition
- Left Ventricular Systolic Dysfunction
- Intervention (Drug)
- Vericiguat tablet
- Intervention (Drug)
- Vericiguat suspension
- Intervention (Drug)
- Placebo tablet
- Intervention (Drug)
- Placebo suspension
- Lead sponsor
- Merck Sharp & Dohme LLC
Record details
- Record id
cardio:ct-nct05714085- Content hash
1b6cd7aa5e5c89f487939e0fcd5b16db6761faee2afa49e19699630d77971c59